Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 25, 2014

UC Santa Barbara Students Get Bexsero to Treat Meningitis B

Novartis provides its second US university with Bexsero for the treatment of meningitis B.

Novartis reported that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB). In the last three months, FDA has approved the use of Bexsero twice in response to MenB outbreaks at US college campuses. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB.
 
Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada, and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug designation.
 
Source: Novartis


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.